Cogent Biosciences Profit Margin 2016-2021 | COGT

Current and historical gross margin, operating margin and net profit margin for Cogent Biosciences (COGT) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Cogent Biosciences net profit margin as of June 30, 2021 is 0%.
Cogent Biosciences Annual Profit Margins
Cogent Biosciences Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.326B $0.008B
Cogent Biosciences Inc. is a biotechnology company. It is focused on developing precision therapies for genetically defined diseases. The company's program consist PLX9486. Cogent Biosciences Inc., formerly known as Unum Therapeutics Inc., is based in CAMBRIDGE, Mass.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76